Skip to main navigation Skip to search Skip to main content

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

  • Ioana Agache*
  • , Jessica Beltran
  • , Cezmi Akdis
  • , Mubeccel Akdis
  • , Carlos Canelo-Aybar
  • , Giorgio Walter Canonica
  • , Thomas Casale
  • , Tomas Chivato
  • , Jonathan Corren
  • , Stefano Del Giacco
  • , Thomas Eiwegger
  • , Davide Firinu
  • , James E. Gern
  • , Eckard Hamelmann
  • , Nicola Hanania
  • , Mika Mäkelä
  • , Irene Hernández-Martín
  • , Parameswaran Nair
  • , Liam O'Mahony
  • , Nikolaos G. Papadopoulos
    • Alberto Papi, Hae Sim Park, Luis Pérez de Llano, Margarita Posso, Claudio Rocha, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Yang Song, Corinna Steiner, Jurgen Schwarze, Pablo Alonso-Coello, Oscar Palomares, Marek Jutel
*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Journal article

368   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science